12-7029-81

antibody from Invitrogen Antibodies

Targeting: IL2 IL-2, TCGF

Provider product page for 12-7029-81

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [21]
Comments [0]
Validations
Other assay [9]

Submit

Product number: 12-7029-81 - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-2 Monoclonal Antibody (MQ1-17H12), PE, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The MQ1-17H12 antibody reacts with human interleukin-2 (IL-2), a 17 kDa T cell growth factor and a major immunoregulatory cytokine. The MQ1-17H12 antibody is a non-neutralizing antibody. Applications Reported: MQ1-17H12 has been reported for use in intracellular flow cytometric analysis. Applications Tested: This MQ1-17H12 antibody has been tested by intracellular staining of stimulated normal human perioheral blood cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
Reactivity: Human
Host: Rat
Conjugate: Yellow dye
Isotype: IgG
Antibody clone number: MQ1-17H12
Vial size: 50 µg
Concentration: 0.2 mg/mL
Storage: 4° C, store in dark, DO NOT FREEZE!

IL2 protein structure - 12-7029-81 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. NKD2 is involved in regulation of the Ca 2+ -NFAT signaling pathway in T cells (A) Representative immunoblot showing expression of NKD2 in lysates from HeLa cells, unstimulated Jurkat T cells, or those stimulated with PMA + ionomycin or anti-CD3 antibody (Ab) for 6 h. beta-Actin, loading control. Data are representative of two independent experiments. (B) Representative immunoblot showing expression of NKD2 in lysates of control or NKD2 knockout (KO) Jurkat T cells generated using two independent sgRNAs (#1 and #3). beta-Actin, loading control. Data are representative of two independent experiments. (C) Representative traces showing averaged SOCE from control (69 cells), NKD2 KO (KO sgRNA #1, 70 cells) Jurkat T cells, or NKD2 KO Jurkat T cells reconstituted for expression of NKD2 (KO sgRNA #1 + NKD2, 68 cells) after TCR stimulation using anti-CD3 antibodies, followed by ionomycin treatment in the presence of external solution containing 2 mM Ca 2+ . Bar graph (right) shows averaged baseline-subtracted SOCE (+-SEM) from three independent experiments with NKD2 KO cells generated using two independent sgRNAs (#1 and #3). (D) Representative immunoblot of NFATc2 levels in nuclear extracts from wild-type (WT) and NKD2 KO (sgRNA #1) Jurkat T cells stimulated with 1 muM ionomycin for indicated times. A nuclear protein, Ku86, was used as a loading control. Bar graph shows the densitometric analysis of relative band intensities of nuclear NFATc2. Data show means +- SEM of poo
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. NKD2-mediated ORAI1 + vesicle trafficking is crucial for the effector function of primary T cells (A) Representative histograms showing levels of NKD2 protein in primary T cells transduced with lentiviral vectors encoding scrambled sgRNA (control), NKD2 sgRNA #1, and NKD2 sgRNA #3, together with those encoding Cas9. Cells were permeabilized and stained with anti-NKD2 Ab. The bar graph (right) shows average (+-SEM) from four independent experiments. (B) Representative traces showing averaged SOCE from primary control (73 cells) and NKD2 KO (KO sgRNA #1, 82 cells; KO sgRNA #3, 71 cells) T cells after TCR stimulation using anti-CD3 Abs, followed by ionomycin treatment in the presence of external solution containing 2 mM Ca 2+ . Bar graph (right) shows averaged baseline-subtracted SOCE (+-SEM) from three independent experiments. (C) Representative histograms showing levels of newly inserted PM-resident ORAI1 protein in primary control and NKD2 KO effector T cells after TCR stimulation. Cells were transduced as described above to induce deletion of NKD2 and stimulated and stained as described in Figure 3B for detection of newly inserted PM-resident ORAI1. Bar graph (right) shows average (+-SEM) of pooled technical replicates from three independent donors. (D) Representative flow plots showing expression of IFN-gamma, IL-2, and TNF in control, NKD2 KO (sgRNA #1), and NKD2 KO (sgRNA #3) cells after re-stimulation with anti-CD3 and anti-CD28 Abs. Bar graph shows means +- SE
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Rapid induction of polyfunctional IL-2-secreting T cells in convalescents and naive individuals after BNT162b2 mRNA vaccination. ( a ) frequencies of spike-reactive cytokine-secreting cells in convalescents (red, n = 50 (m11), n = 54 (vacc), n = 23 (boost)), and naive individuals (blue, n = 39 (m11), n = 49 (vacc), n = 40 (boost)) at month 11 after SARS-CoV-2 infection, two weeks after BNT162b2 mRNA prime vaccination (vacc) and 2 weeks after boost vaccination (boost). b Heatmap revealing frequencies of individuals bearing S1-reactive mono- or polyfunctional cytokine-secreting cells; convalescents (c), naive individuals (n). c Median and standard deviation for S1-reactive cytokine-secreting cells. d , e S1-reactive IL-2 and IFNgamma-producing CD4 and CD8 T cells in convalescents (red, n = 19) and naive individuals (blue, n = 31) determined directly ex vivo by flow cytometry using intracellular cytokine staining. Statistical analyses by ANOVA, two-sided Mann-Whitney and two-sided Wilcoxon signed-rank tests ( a , e ). n.s. denotes not significant; * p < 0.05; ** p < 0.01; **** p < 0.0001.
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 FIGURE Platelets suppress T-cell activation by A549 cell an effect reversed by eptifibatide. (A) Representative flow cytometry dot plots and (B) summary data demonstrating IL-2 expression in Jurkat cells after 6 h of co-culture with A549 cells that were pre-treated with/without platelets and eptifibitide (10 muM). N = 7. *, p -value
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Composition of SARS-CoV-2-specific T cells in convalescent HIV-negative and HIV-positive individuals. Intracellular cytokine staining (ICS) was performed to detect cytokine-producing T cells to the indicated peptide pools in HIV-negative (HIV-, n = 12) and HIV-positive individuals (HIV+, n = 11). a Representative flow cytometric plots for the identification of antigen-specific CD4 T cells based on double expression (CD154 + IFN-gamma + , CD154 + IL-2 + , and CD154 + TNF-alpha + ) following 6-h stimulation with media alone (control) or overlapping SARS-CoV-2 peptides against Spike pool 1 and 2 (Spike), Nucleoprotein (N), and Membrane protein (M) directly ex vivo. b Frequency of aggregated CD4 T-cell responses (CD154 + IFN-gamma + , CD154 + IL-2 + , and CD154 + TNF-alpha + ) against Spike, M/N or combined (Spike and M/N) peptide pools (HIV-, n = 12; HIV+, n = 11). Error bars represent SEM. c Pie charts representing the relative proportions of Spike, M/N, or total (combined Spike and M/N) CD4 T-cell responses for one (gray), two (green) or three (dark blue) cytokines, and pie arcs denoting IFN-gamma, TNF-alpha and IL-2. d Representative flow cytometric plots for the identification of antigen-specific CD8 T cells based on the expression of (IFN-gamma + , TNF-alpha + , and IL-2 + ) against the specified peptide pools or media alone (control). e Proportion of aggregated CD8 T-cell responses against Spike, M/N or combined (Spike and M/N) responses in HIV- ( n = 12) and HIV+ (
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Decreased frequencies of gammadelta T cells expressing Th1 cytokines in LTB comorbidities. Peripheral blood mononuclear cells (PBMCs) were either untreated or treated with Mtb or positive control antigens for 18 h. The absolute (unstimulated, UNS) and antigen-stimulated (PPD, WCL, P/I) net frequencies of Th1 (IFNgamma, IL-2, TNFalpha) cytokines were shown in LTB DM (n = 20), LTB PDM (n = 20), and LTB NDM (n = 20) groups. Geometric mean values were represented using bars, and every circle denotes a single individual. Kruskal-Wallis test with multiple Dunn's comparison was used to determine the p values.
Conjugate: Yellow dye